INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 413m ago
HOUSE PTR12m ago
SEC 13F12m ago
ROBINHOOD CHAIN12m ago
SEC FORM 4/Option exerciseVerified data

Zojwalla Naseem reported OLMA

Chief Medical Officer · Olema Pharmaceuticals, Inc. · Olema Pharmaceuticals, Inc. — Stock Option (Right to Buy)

Side
M
Value
—
Shares
40.0K
Price
—
Executed
Dec 19, 2025
Disclosed
Dec 23, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Dec 19 executedDec 23, 2025 disclosed

OLMA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+9 / 25

    No reported dollar value · 34.8% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · OLMA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    OJ
    O'Byrne JasonCHIEF FINANCIAL OFFICER
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    650.0K sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    15
    RP
    Raman PrakashDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.5K sh
    		Jun 18, 2026Jun 23, 2026
    traded Jun 18, 2026
    		+5dSEC FORM 4

    Evidence

    11
    HC
    Harmon CyrusDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.5K sh
    		Jun 18, 2026Jun 23, 2026
    traded Jun 18, 2026
    		+5dSEC FORM 4

    Evidence

    15
    HG
    Hrustanovic GorjanDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.5K sh
    		Jun 18, 2026Jun 23, 2026
    traded Jun 18, 2026
    		+5dSEC FORM 4

    Evidence

    9
    RP
    Raman PrakashDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    24.1K sh
    		Apr 28, 2026Apr 29, 2026
    traded Apr 28, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RP
    Raman PrakashDirector
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    2,911 sh
    		Apr 28, 2026Apr 29, 2026
    traded Apr 28, 2026
    		+1dSEC FORM 4

    Evidence

    19
    AL
    Austin Sasha LuVP of Finance and Controller
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    29.3K sh
    		Feb 2, 2026Feb 17, 2026
    traded Feb 2, 2026
    		+15dSEC FORM 4

    Evidence

    31
    AL
    Austin Sasha LuVP of Finance and Controller
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    11.7K sh
    		Feb 2, 2026Feb 17, 2026
    traded Feb 2, 2026
    		+15dSEC FORM 4

    Evidence

    2
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    250.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BS
    Bohen SeanDirector, PRESIDENT AND CEO
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    275.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BS
    Bohen SeanDirector, PRESIDENT AND CEO
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    850.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    ZN
    Zojwalla NaseemCHIEF MEDICAL OFFICER
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    106.3K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    2
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    106.3K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    ZN
    Zojwalla NaseemCHIEF MEDICAL OFFICER
    OLMAOlema Pharmaceuticals, Inc.
    Grant or award
    		A—
    250.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    33
    HC
    Harmon CyrusDirector
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$269K
    10.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    30
    HC
    Harmon CyrusDirector
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$102K
    3,489 sh
    		Jan 14, 2026Jan 16, 2026
    traded Jan 14, 2026
    		+2dSEC FORM 4

    Evidence

    34
    KC
    Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$107K
    3,822 sh
    		Jan 13, 2026Jan 15, 2026
    traded Jan 13, 2026
    		+2dSEC FORM 4

    Evidence

    44
    KC
    Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF.
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$2.87M
    100.0K sh
    		Jan 15, 2026Jan 15, 2026
    traded Jan 15, 2026
    		+0dSEC FORM 4

    Evidence

    30
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Open-market sale
    		SELL$429K
    15.0K sh
    		Jan 14, 2026Jan 14, 2026
    traded Jan 14, 2026
    		+0dSEC FORM 4

    Evidence

    9
    MC
    Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
    OLMAOlema Pharmaceuticals, Inc.
    Option exercise
    		M$244K
    50.0K sh
    		Jan 14, 2026Jan 14, 2026
    traded Jan 14, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001905871-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 19, 2025
    Published
    Dec 23, 2025
    Ingested by INSIDER
    Nov 5, 04:26 UTC
    Last re-read
    Nov 5, 04:26 UTC

    Extracted facts

    Filer
    Zojwalla Naseem
    Role
    Chief Medical Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Olema Pharmaceuticals, Inc. — Stock Option (Right to Buy)
    Ticker
    OLMA
    Shares
    40.0K
    Price per share
    $0
    Execution date (reported)
    Dec 19, 2025
    Owned after transaction
    155.0K shares
    Days from execution to publication
    4

    What this establishes

    Zojwalla Naseem filed this Form 4 reporting a option exercise of OLMA on Dec 19, 2025. It became public on Dec 23, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Zojwalla Naseemcik:0001905871
    Issuer
    Olema Pharmaceuticals, Inc.cik:0001750284

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.